Calliditas Therapeutics AB (Nasdaq: CALT) is majority-owned by Asahi Kasei following its acquisition of over 90% of outstanding shares (September 2024). The company demonstrates strong commercial traction, with preliminary Net TARPEYO revenues of $100–102m for 2023, representing over 170% year-over-year growth compared to 2022.
Cyborg Score Rationale
Calliditas has achieved commercial viability with TARPEYO generating substantial and growing revenues in a focused rare disease market. Strategic backing from Asahi Kasei provides capital and operational support. However, significant dependence on a single product and potential delisting from major exchanges create near-term execution risks.
Top Insights
Q2 2024 TARPEYO net sales reached SEK 493.4 million, demonstrating sustained commercial momentum in orphan nephropathy.
Following Asahi Kasei's acquisition (September 2024), the company applied for delisting from Nasdaq Stockholm and delisting of ADSs from Nasdaq Global Select Market (effective around September 2024).
Narrow therapeutic focus on renal and hepatic rare diseases limits addressable market but allows deep product expertise and patient engagement.
The company specializes in rare diseases with operations across the United States, Europe, and Asia.
Named Competitors
IMPDH Inhibitors — Treatment options for rare kidney diseases and anemia
Corticosteroids — Standard systemic immunosuppressants for renal indications
Immunosuppressive Therapies — Broad immunology and rare disease portfolio
Recent Developments
(June 2026) Calliditas continues operating as a subsidiary of Asahi Kasei following completion of 90%+ ownership acquisition and delisting from major public markets (September 2024).
(Q2 2024) Strong TARPEYO revenue growth with SEK 493.4 million in quarterly net sales and adjusted operating profit of SEK 70.2 million.
(March 2024) FDA granted seven-year orphan drug exclusivity extension for Nefecon (oral budesonide formulation) for IgA nephropathy treatment.
Open the full interactive Calliditas Therapeutics AB report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.